spacer
home > ebr > winter 2003 > cowpox to conjugates: trends in vaccines
PUBLICATIONS
European Biopharmaceutical Review

Cowpox to Conjugates: Trends in Vaccines

Vaccines are a group of products that include some of the oldest biological pharmaceutical entities. They are also an area where new techniques and manufacturing technologies are giving rise to significant growth. While eradication of some historic diseases has led to a lower need for prophylaxis, the resurgent threat of bioterrorism has given impetus to finding new and rapid methods for producing vaccines against a range of new and old threats, such as Anthrax.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ian Sellick, Director of Marketing at Pall Life Sciences

Ian Sellick is Marketing Director with Pall Life Sciences, where he is responsible for the spectrum of membrane-based technologies for separations and purification, and processing systems based on those technologies. Ian has 20 years' experience in the separations industries, the last eight with Pall Corporation. He holds an Honours degree in Zoology (with Cell Biology and Pharmacology) from the University of Bristol, and has post-graduate research experience in mucin biochemistry, growth dynamics and polymorphic isozymes of fish. Ian has published a large number of articles and papers, including papers on separations for food and dairy derived products, as well as the Institute of Brewing's book on beer filtration. He speaks regularly at conferences on separations for the biotechnology industry.

spacer
Ian Sellick
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

PHASE II & IIa Clinical Trials

21-22 February 2012, Lancaster London Hotel, London

Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >>

 
News and Press Releases

Norwich Expands Capabilities for Phase I-III Clinical Trials

Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.